Business
Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power
About this update from Quince Therapeutics, Inc.
[{"type":"text","content":" SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nQuince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the appointment of Dr. William Whitehouse, Honorary Clinical Associate Professor of the School of Medicine at the University of Nottingham, and recently retired Consultant Paediatric Neurologist at Nottingham Children’s Hospital, Nottingham University Hospitals NHS Trust, to the company’s Scientific Advisory Board (SAB). Dr. Whitehouse joins seven founding members of Quince’s SAB comprised of leading experts in biochemistry, neurology, immunology, hematology, pharmacology, and clinical practice.\n\n\nDr. Mauro Magnani, Ph.D., Chair of Quince’s Scientific Advisory Board, said, “We are very pleased to welcome a clinician and researcher of Dr. Whitehouse’s caliber as a new member of Quince’s SAB. As a renowned expert in the rare pediatric neurodegenerative disease Ataxia-Telangiectasia (A-T), we look forward to his valuable contribution and perspective as we support Quince on their mission to unlocking the power of a patient’s own biology for the treatment of rare diseases.”\n\n\nDr. William Whitehouse said, “I look forward to collaborating with the distinguished members of Quince’s management team, Board of Directors, and Scientific Advisory Board to support the advancement of the company’s lead asset EryDex for the treatment of patients with A-T. With the potential to be a first to market treatment for the underserved A-T patient population, I am particularly pleased to provide counsel and lend perspective from my clinical experience caring for patients with A-T over the past 20 years.”\n\n\nDr. William Whitehouse is an Honorary Clinical Associate Professor of the School of Medicine at the University of Nottingham, England, and a recently retired Consultant Paediatric Neurologist at Nottingham Children’s Hospital, Nottingham University Hospitals NHS Trust, one of England’s largest acute teaching trusts. His main clinical and research interests include A-T in children and young people, as well as epilepsies, headache, and transient loss of consciousness in children. Dr. Whitehouse’s interest in A-T began with his clinical academic post at Nottingham Children’s Hospital and the re-launching the U.K.'s na...